Clinical trials and meta-analyses examining the efficacy of pneumococcal polysaccharide vaccine (Pneumovax 23®) in adults have produced conflicting data. This Viewpoint discusses a study designed to ...

Pfzier announced topline results from a second phase 3 trial investigating its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) for the prevention of invasive disease and pneumonia ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

An additional dose of a pneumococcal vaccine, either 23-valent pneumococcal polysaccharide vaccine (PPV23) or 20-valent pneumococcal conjugate vaccine (PCV20), for new care home residents upon entry ...

Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.

Vaccines that protect people from infection by Streptococcus pneumoniae, which kills up to one million children ever year worldwide, train the immune system to recognize the pathogen’s thick sugar ...

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative ...